130 related articles for article (PubMed ID: 15744746)
1. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.
Nowak AK; Stockler MR; Chow PK; Findlay M
Cancer; 2005 Apr; 103(7):1408-14. PubMed ID: 15744746
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen for hepatocellular carcinoma.
Nowak A; Findlay M; Culjak G; Stockler M
Cochrane Database Syst Rev; 2004; (3):CD001024. PubMed ID: 15266436
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.
Barbare JC; Bouché O; Bonnetain F; Raoul JL; Rougier P; Abergel A; Boige V; Denis B; Blanchi A; Pariente A; Milan C; Bedenne L
J Clin Oncol; 2005 Jul; 23(19):4338-46. PubMed ID: 15994145
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.
Chow PK
Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294
[No Abstract] [Full Text] [Related]
5. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.
Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J
Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.
Schoppmeyer K; Weis S; Mössner J; Fleig WE
Cochrane Database Syst Rev; 2009 Jul; (3):CD006745. PubMed ID: 19588401
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.
Riestra S; Rodriguez M; Delgado M; Suárez A; González N; de la Mata M; Diaz G; Miño-Fugarolas G; Rodrigo L
J Clin Gastroenterol; 1998 Apr; 26(3):200-3. PubMed ID: 9600369
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma: A retrospective matched-cohort study.
Zeeneldin AA; Eid SM; Darweesh AD; Moneer MM; Saadeldin M
J Egypt Natl Canc Inst; 2014 Mar; 26(1):1-7. PubMed ID: 24565676
[TBL] [Abstract][Full Text] [Related]
10. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme).
Lancet; 1998 Jul; 352(9121):17-20. PubMed ID: 9800740
[TBL] [Abstract][Full Text] [Related]
12. Is human hepatocellular carcinoma a hormone-responsive tumor?
Di Maio M; Daniele B; Pignata S; Gallo C; De Maio E; Morabito A; Piccirillo MC; Perrone F
World J Gastroenterol; 2008 Mar; 14(11):1682-9. PubMed ID: 18350599
[TBL] [Abstract][Full Text] [Related]
13. Hormonal treatment of human hepatocellular carcinoma.
Di Maio M; De Maio E; Morabito A; D'Aniello R; De Feo G; Gallo C; Perrone F
Ann N Y Acad Sci; 2006 Nov; 1089():252-61. PubMed ID: 17261772
[TBL] [Abstract][Full Text] [Related]
14. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift.
Tan CK; Chow PK; Findlay M; Wong C; Machin D
J Gastroenterol Hepatol; 2000 Jul; 15(7):725-9. PubMed ID: 10937676
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen in hepatocellular carcinoma.
Chow P; Kiat TC; Choo TB; Machin D
Lancet; 1998 Sep; 352(9130):819-20. PubMed ID: 9737316
[No Abstract] [Full Text] [Related]
16. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma.
Elba S; Giannuzzi V; Misciagna G; Manghisi OG
Ital J Gastroenterol; 1994 Mar; 26(2):66-8. PubMed ID: 8032079
[TBL] [Abstract][Full Text] [Related]
17. Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.
Jia WD; Zhang CH; Xu GL; Ge YS; Wang W
Hepatogastroenterology; 2010; 57(98):292-9. PubMed ID: 20583430
[TBL] [Abstract][Full Text] [Related]
18. [Systemic treatment for hepatocellular carcinoma].
Spangenberg HC; Zuber-Jerger I; Thimme R; Blum HE; Von Weizsäcker F
Zentralbl Chir; 2003 Nov; 128(11):906-10. PubMed ID: 14669110
[TBL] [Abstract][Full Text] [Related]
19. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials.
Thiele M; Albillos A; Abazi R; Wiest R; Gluud LL; Krag A
Liver Int; 2015 Aug; 35(8):2009-16. PubMed ID: 25581713
[TBL] [Abstract][Full Text] [Related]
20. [Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature].
Recchia F; Passalacqua G; Rodorigo C; Belli L; Morgante A; Rabitti G
Minerva Med; 1989 Dec; 80(12):1363-6. PubMed ID: 2560153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
